Bristol To Overcome Sprycel Uptake “Resistance” By Encouraging Faster Switching
This article was originally published in The Pink Sheet Daily
Executive Summary
Bristol-Myers Squibb reports modest sales of $25 million for Sprycel during the oncologic’s first six months on the market.